Allen Barbieri's Contact Details

Allen Barbieri's Company Details

PsiloSterics

Seattle, Washington, United States • 2 Employees
Pharmaceuticals

We have created a vast library of patentable and highly active new chemical entities (NCEs) that are designed to target serotonin receptors in a specific manner to enable the treatment of multiple neurological diseases and disorders. Our strategy leverages significant advantages in the areas of patent and regulatory exclusivity. Our Next-Gen NCEs are novel and patentable, unlike naturally-occurring tryptamines. PsiloSterics exclusively owns all intellectual property rights associated with its proprietary NCE platform.While First-Gen psychedelic drug development has been largely focused on known drugs in new formulations or regimens, our Next-Gen approach primarily focuses on advancing novel drugs with 5-HT receptor activity to treat a host of neurological disorders.Psychedelic drugs can address multiple conditions affecting large population groups representing sizable markets. However, many First-Gen natural and synthetic analogs are not optimized for therapeutic use. Our NCE platform will create safer and more accessible drugs that can be personalized on a per-indication, per-patient basis. We look forward to collaborating with partners in the industry to launch the next generation of psychedelic-inspired medicines.